Bipolar disorder is one of the most prevalent psychiatric diseases in developed countries, and virtually all major psychiatric associations recommend lithium as the first line therapy for bipolar patients in the depressive phase of the illness, despite relatively low response rate for the drug and relatively high likelihood of side effects. However, no predictive criteria which indicate an individual patient’s responsiveness to lithium are employed clinically. In this work, we present preliminary findings demonstrating an association between baseline, multimodal neuroimaging measurements and lithium treatment outcome.
This abstract and the presentation materials are available to members only; a login is required.